Spectrum Pharma (SPPI) Tops Q4 EPS by 3c
Get Alerts SPPI Hot Sheet
EPS Growth %: +100.0%
Financial Fact:
Other income, net: 372K
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Spectrum Pharma (NASDAQ: SPPI) reported Q4 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33).
“ROLONTIS is in active review by the FDA and we are preparing to launch shortly following approval,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. “We believe this market represents a significant commercial opportunity and our prelaunch activities are well underway. We have a podium presentation on poziotinib in a few short weeks, we have taken steps to adjust our strategy and we have multiple data catalysts in 2020. I look forward to updating you on our progress throughout the year.”
For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) stock slips despite earnings beat
- Unilever PLC (UL) Q1 Revenue Misses Estimates
- Cboe Global Markets (CBOE) Realigns Digital Asset Business
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!